γ-phenoxy-isovaleric acid methyl ester | 120888-55-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: γ-phenoxy-isovaleric acid methyl ester
• 英文别名: γ-Phenoxy-isovaleriansaeure-methylester；Methyl 3-methyl-4-phenoxybutanoate
• CAS: 120888-55-3
• 化学式: C₁₂H₁₆O₃
• 分子量: 208.257
• InChiKey: TXHLBYIRNSEPQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  methyl 4-bromo-3-methylbut-2-enoate 在 甲醇 、 potassium carbonate 、 铂 作用下， 生成 γ-phenoxy-isovaleric acid methyl ester
  参考文献：
  名称：

  Canonica et al., Rendiconti - Istituto Lombardo Accademia di Scienze e Lettere, A: Scienze Matematiche, Fisiche, Chimiche e Geologiche, 1954, vol. 87, p. 257,269

  摘要：

  DOI：

文献信息

• Benzodioxane prostacyclin analogues, their preparation and use
  申请人：SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD.

  公开号：EP0297923A1

  公开（公告）日：1989-01-04

  Benzodioxane Prostacyclin Analogues represented by the formula: wherein R₁ is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, or phenoxyalkyl; R₂ is hydrogen, lower alkyl, or aralkyl; R₁ is hydrogen or protecting group; A is ethylene or vinylene; and the wavy line indicates α or β configuration or their mixture; or a salt thereof having an antiulcer activity and platelet aggregation inhibitory activity.

  由式表示的苯并二恶烷前列环素类似物： 其中 R₁ 是烷基、烯基、炔基、环烷基、环烷基烷基或苯氧基烷基；R₂ 是氢、低级烷基或芳烷基；R₁ 是氢或保护基；A 是乙烯或乙烯基；波浪线表示 α 或 β 构型或它们的混合物；或其盐具有抗溃疡活性和血小板聚集抑制活性。
• Hospital-acquired infections among chronic hemodialysis patients
  作者：Erika M.C. D'Agata、David B. Mount、Valerie Thayer、William Schaffner

  DOI：10.1016/s0272-6386(00)70044-8

  日期：2000.6

  The epidemiological characteristics of nosocomial infections among patients requiring chronic hemodialysis, a high-risk and rapidly growing population, have not been fully elucidated. During a 30 month cohort study, rates of bloodstream infections (BSIs), urinary tract infections (UTIs), pneumonia, and diarrhea caused by Clostridium difficile and the distribution of pathogens among hospitalized chronic hemodialysis patients were compared with hospitalized patients not requiring chronic hemodialysis, To identify risk factors for developing a nosocomial infection among chronic hemodialysis patients, a matched case-control study was performed. A total of 1,557 nosocomial infections were detected during 1,317 of 68,361 admissions (2%). Of these, 47 nosocomial infections occurred in chronic hemodialysis patients during 31 of 578 admissions (5%). Nosocomial infections were significantly more frequent among the chronic hemodialysis group (9.1/1,000 patient-days) compared with the non-chronic hemodialysis group (3.8/1,000 patient-days; relative risk [RR], 2.4; 95% confidence interval [CI], 1.8 to 3.2; P < 0.001). UTIs were the most common nosocomial infections among chronic hemodialysis patients, accounting for 47% of all infections in this population. UTIs were significantly more common among chronic hemodialysis patients (4.2/1,000 patient-days) compared with non-chronic hemodialysis patients (0.7/1,000 patient-days; RR, 6.2; 95% CI, 3.8 to 9.5; P < 0.001). Among chronic hemodialysis patients, Candida spp and enterococci were the most common pathogens in contrast to coagulase-negative staphylococci and Staphylococcus aureus among patients not requiring hemodialysis. Using conditional logistic regression, a greater index of comorbidity was significantly associated with nosocomial infections among the chronic hemodialysis population (odds ratio, 3.6; 95% CI, 1.2 to 10.7; P = 0.02), Chronic hemodialysis patients are at a substantially greater risk for developing a nosocomial infection compared with other hospitalized patients. (C) 2000 by the National Kidney Foundation, Inc.
• US4902811A
  申请人：——

  公开号：US4902811A

  公开（公告）日：1990-02-20
• US7169598B2
  申请人：——

  公开号：US7169598B2

  公开（公告）日：2007-01-30
• US7527809B2
  申请人：——

  公开号：US7527809B2

  公开（公告）日：2009-05-05